Results 161 to 170 of about 6,404 (193)
Some of the next articles are maybe not open access.
Safety of Recombinant Zoster Vaccine in Rheumatology Patients
Southern Medical Journal, 2022Recombinant zoster vaccine (RZV) is Food and Drug Administration approved for the prevention of herpes zoster (shingles) in adults 50 years old and older. Immunocompromised subjects were excluded from the pivotal vaccine trials. We studied the safety of this vaccine in our university-affiliated rheumatology practice.This was a single-center ...
Syed, Raza +3 more
openaire +2 more sources
Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data [PDF]
Vaccine, 2023 Recombinant zoster vaccine (RZV) is recommended for individuals ≥ 50 years of age for protection against herpes zoster (HZ). This study quantifies RZV coverage and assesses predictors for RZV vaccination using a U.S. claims database.
Kunal Mishra +2 more
exaly +2 more sources
Recombinant Zoster Vaccine (Shingrix) to Prevent Herpes Zoster
Nursing for Women's Health, 2018Women ages 50 years and older are at risk for herpes zoster, a reactivated virus from varicella zoster virus (chickenpox) that causes a painful vesicular rash and can result in postherpetic neuralgia. It is estimated that one in three adults will be affected by herpes zoster in their lifetime.
Jacqueline R. Sly, Allyssa L. Harris
openaire +2 more sources
Efficacy of Recombinant Zoster Vaccine in Patients With Inflammatory Bowel Disease
Clinical Gastroenterology and Hepatology, 2022Individuals with inflammatory bowel disease (IBD) have an increased risk of herpes zoster (HZ) infection. Although the efficacy of recombinant zoster vaccine (RZV) is high among immunocompetent individuals, little is known about its effect among immunosuppressed individuals with IBD.We conducted a retrospective cohort study among individuals in the ...
Nabeel Khan +2 more
exaly +3 more sources
Insurance reimbursements for recombinant zoster vaccine in the private sector
Vaccine, 2021A two-dose series of the recombinant zoster vaccine (RZV, Shingrix) was licensed by the Food and Drug Administration in 2017 and recommended by the Advisory Committee on Immunization Practices in 2018 for adults in the United States age 50 years and older.
Andrew J. Leidner +4 more
openaire +2 more sources
Presumed Herpes Zoster Ophthalmicus Reactivation Following Recombinant Zoster Vaccination
Cornea, 2020Purpose: To report a case of herpes zoster ophthalmicus (HZO) reactivation after recombinant zoster vaccination. Methods: A 78-year-old woman, with a history of HZO 20 years ago, was referred for progressive corneal thinning in her left eye that started 1 week after her second dose ...
Samir, Jabbour +3 more
openaire +2 more sources
Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention
Expert Review of Vaccines, 2018 Introduction: GSK has developed a two-dose adjuvanted recombinant zoster vaccine (Shingrix, RZV) to protect people aged ≥50 years (50+) against herpes zoster (HZ) and its complications.
Arnaud M Didierlaurent +2 more
exaly +2 more sources
Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease
Journal of Crohn's and Colitis, 2022Abstract Background and Aims Patients with inflammatory bowel disease [IBD] have an increased risk of contracting herpes zoster [HZ] infection. However, vaccination rates for HZ are low among IBD patients. A contributing factor may be fear of an IBD flare associated with vaccination.
Nabeel Khan +4 more
openaire +2 more sources
Recombinant Zoster Vaccine (Shingrix®): A Review in Herpes Zoster
Drugs & Aging, 2018Shingrix® is a recombinant zoster vaccine (RZV) that contains a varicella zoster virus glycoprotein E antigen and the AS01B adjuvant system. The subunit vaccine is approved for the prevention of herpes zoster (HZ) [EU, USA, Japan, Canada and Australia] and postherpetic neuralgia (PHN) [EU and Australia] in adults aged ≥ 50 years.
openaire +2 more sources
Impact of a pharmacist-driven recombinant zoster vaccine administration program
Journal of the American Pharmacists Association, 2021To determine whether a pharmacist-driven recombinant zoster vaccine (RZV) administration pilot program within a human immunodeficiency virus/infectious diseases clinic setting increased the completion of the 2-dose series when compared with standard care.In this retrospective cohort study, the patients enrolled in a pharmacist-driven RZV administration
Allison M. Porter, Patricia Pecora Fulco
openaire +2 more sources